The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia
Open accessAbstract
BACKGROUND: Mutations in fibroblast growth factor 23 (FGF-23) cause autosomal dominant hypophosphatemic rickets. Clinical and laboratory findings in this disorder are similar to those in oncogenic osteomalacia, in which tumors abundantly express FGF-23 messenger RNA, and to those in X-linked hypophosphatemia, which is caused by inactivating mutations in a phosphate-regulating endopeptidase called PHEX. Recombinant FGF-23 induces phosphaturia and hypophosphatemia in vivo, suggesting that it has a role in phosphate regulation. To determine whether FGF-23 circulates in healthy persons and whether it is elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, an immunometric assay was developed to measure it. METHODS: Using affinity-purified, polyclonal antibodies against [Tyr223]FGF-23(206-222)amide and [Tyr224]FGF-23(225-244)amide, we developed a two-site enzyme-linked immunosorbent assay that detects equivalently recombinant human FGF-23, the mutant form in which glutamine is substituted for arginine at position 179 (R179Q), and synthetic human FGF-23(207-244)amide. Plasma or serum samples from 147 healthy adults (mean [+/-SD] age, 48.4+/-19.6 years) and 26 healthy children (mean age, 10.9+/-5.5 years) and from 17 patients with oncogenic osteomalacia (mean age, 43.0+/-13.3 years) and 21 patients with X-linked hypophosphatemia (mean age, 34.9+/-17.2 years) were studied. RESULTS: Mean FGF-23 concentrations in the healthy adults and children were 55+/-50 and 69+/-36 reference units (RU) per milliliter, respectively. Four patients with oncogenic osteomalacia had concentrations ranging from 426 to 7970 RU per milliliter, which normalized after tumor resection. FGF-23 concentrations were 481+/-528 RU per milliliter in those with suspected oncogenic osteomalacia and 353+/-510 RU per milliliter (range, 31 to 2335) in those with X-linked hypophosphatemia. CONCLUSIONS: FGF-23 is readily detectable in the plasma or serum of healthy persons and can be markedly elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, suggesting that this growth factor has a role in phosphate homeostasis. FGF-23 measurements might improve the management of phosphate-wasting disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
White, K. E., Evans, W. E., O'Riordan, J. L. H., Speer, M. C., Econs, M. J., Lorenz-Depiereux, B., Grabowski, M., Meitinger, T., & Strom, T. M. (2000) · Nature Genetics · doi:10.1038/81664 · Cited by 1,528
Self-citationCloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101545198 · Cited by 1,457
Nussbaum, S. R., Zahradnik, R. J., Lavigne, J. R., Brennan, G. L., Nozawa-Ung, K., Kim, L. Y., Keutmann, H. T., Wang, C. A., Potts, J. T., & Segre, G. V. (1987) · Clinical Chemistry · doi:10.1093/clinchem/33.8.1364 · Cited by 808
Self-citationYamashita, T., Yoshioka, M., & Itoh, N. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3696 · Cited by 554
Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23
White, K. E., Carn, G., Lorenz-Depiereux, B., Benet-Pages, A., Strom, T. M., & Econs, M. J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00064.x · Cited by 493
Self-citationShimada, T. (2002) · Endocrinology · doi:10.1210/en.143.8.3179 · Cited by 446
FGF-23 Inhibits Renal Tubular Phosphate Transport and Is a PHEX Substrate
Bowe, A. E., Finnegan, R., Jan de Beur, S. M., Cho, J., Levine, M. A., Kumar, R., & Schiavi, S. C. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5084 · Cited by 344
White, K. E. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.497 · Cited by 329
Self-citationBai, X.-Y., Miao, D., Goltzman, D., & Karaplis, A. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210490200 · Cited by 276
Octreotide Therapy for Tumor-Induced Osteomalacia
Seufert, J., Ebert, K., Müller, J., Eulert, J., Hendrich, C., Werner, E., Schütze, N., Schulz, G., Kenn, W., Richtmann, H., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010839 · Cited by 234
Cited by
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis
Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., & Yamashita, T. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301264 · Cited by 1,883
Klotho converts canonical FGF receptor into a specific receptor for FGF23
Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S., & Yamashita, T. (2006) · Nature · doi:10.1038/nature05315 · Cited by 1,850
Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
Gutiérrez, O. M., Mannstadt, M., Isakova, T., Rauh-Hain, J. A., Tamez, H., Shah, A., Smith, K., Lee, H., Thadhani, R., Jüppner, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706130 · Cited by 1,727
Self-citationShimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., & Yamashita, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19081 · Cited by 1,596
Regulation of Fibroblast Growth Factor-23 Signaling by Klotho
Kurosu, H., Ogawa, Y., Miyoshi, M., Yamamoto, M., Nandi, A., Rosenblatt, K. P., Baum, M. G., Schiavi, S., Hu, M.-C., Moe, O. W., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c500457200 · Cited by 1,366
Gutierrez, O., Isakova, T., Rhee, E., Shah, A., Holmes, J., Collerone, G., Ju[Combining Diaeresis]ppner, H., & Wolf, M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010052 · Cited by 921
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Kurosu, H., Choi, M., Ogawa, Y., Dickson, A. S., Goetz, R., Eliseenkova, A. V., Mohammadi, M., Rosenblatt, K. P., Kliewer, S. A., & Kuro-o, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704165200 · Cited by 748
Fliser, D., Kollerits, B., Neyer, U., Ankerst, D. P., Lhotta, K., Lingenhel, A., Ritz, E., & Kronenberg, F. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080936 · Cited by 699
Larsson, T., Nisbeth, U. L. F., Ljunggren, Ö., Jüppner, H., & Jonsson, K. B. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00328.x · Cited by 689
Self-citationFGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting
Riminucci, M., Collins, M. T., Fedarko, N. S., Cherman, N., Corsi, A., White, K. E., Waguespack, S., Gupta, A., Hannon, T., Econs, M. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18399 · Cited by 657
Self-citationHu, M. C., Shiizaki, K., Kuro-o, M., & Moe, O. W. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183727 · Cited by 587
Sitara, D., Razzaque, M. S., Hesse, M., Yoganathan, S., Taguchi, T., Erben, R. G., J+APw-ppner, H., & Lanske, B. (2004) · Matrix Biology · doi:10.1016/j.matbio.2004.09.007 · Cited by 542
Lorenz-Depiereux, B., Bastepe, M., Benet-Pagès, A., Amyere, M., Wagenstaller, J., Müller-Barth, U., Badenhoop, K., Kaiser, S. M., Rittmaster, R. S., Shlossberg, A. H., et al. (2006) · Nature Genetics · doi:10.1038/ng1868 · Cited by 529
Self-citationClinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
Haffner, D., Emma, F., Eastwood, D. M., Biosse Duplan, M., Bacchetta, J., Schnabel, D., Wicart, P., Bockenhauer, D., Santos, F., Levtchenko, E., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0152-5 · Cited by 521
Ferrari, S. L., Bonjour, J.-P., & Rizzoli, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1039 · Cited by 518
Regulation of Fibroblastic Growth Factor 23 Expression but Not Degradation by PHEX
Liu, S., Guo, R., Simpson, L. G., Xiao, Z.-S., Burnham, C. E., & Quarles, L. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304544200 · Cited by 508
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia
Benet-Pagès, A., Orlik, P., Strom, T. M., & Lorenz-Depiereux, B. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi034 · Cited by 507
Larsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, Ö., Tenenhouse, H. S., Jüppner, H., & Jonsson, K. B. (2004) · Endocrinology · doi:10.1210/en.2003-1768 · Cited by 499
Self-citationKrajisnik, T., Björklund, P., Marsell, R., Ljunggren, O., Åkerström, G., Jonsson, K. B., Westin, G., & Larsson, T. E. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0267 · Cited by 476
Self-citationCirculating FGF-23 Is Regulated by 1α,25-Dihydroxyvitamin D3 and Phosphorus in Vivo
Saito, H., Maeda, A., Ohtomo, S.-I., Hirata, M., Kusano, K., Kato, S., Ogata, E., Segawa, H., Miyamoto, K.-I., & Fukushima, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408903200 · Cited by 471
Endocrine functions of bone in mineral metabolism regulation
Quarles, L. D. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36479 · Cited by 459
Parker, B. D., Schurgers, L. J., Brandenburg, V. M., Christenson, R. H., Vermeer, C., Ketteler, M., Shlipak, M. G., Whooley, M. A., & Ix, J. H. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-10-201005180-00004 · Cited by 457
Regulation of C-Terminal and Intact FGF-23 by Dietary Phosphate in Men and Women
Burnett, S.-A. M., Gunawardene, S. C., Bringhurst, F. R., Jüppner, H., Lee, H., & Finkelstein, J. S. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060507 · Cited by 455
Self-citationThe FGF23–Klotho axis: endocrine regulation of phosphate homeostasis
Razzaque, M. S. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.196 · Cited by 448
FGF-23 Associates with Death, Cardiovascular Events, and Initiation of Chronic Dialysis
Kendrick, J., Cheung, A. K., Kaufman, J. S., Greene, T., Roberts, W. L., Smits, G., & Chonchol, M. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010121224 · Cited by 448
Gattineni, J., Bates, C., Twombley, K., Dwarakanath, V., Robinson, M. L., Goetz, R., Mohammadi, M., & Baum, M. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90742.2008 · Cited by 438
Shimada, T., Urakawa, I., Yamazaki, Y., Hasegawa, H., Hino, R., Yoneya, T., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.102 · Cited by 429
Chong, W. H., Molinolo, A. A., Chen, C. C., & Collins, M. T. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0006 · Cited by 429
Perwad, F., Azam, N., Zhang, M. Y. H., Yamashita, T., Tenenhouse, H. S., & Portale, A. A. (2005) · Endocrinology · doi:10.1210/en.2005-0777 · Cited by 425
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Degirolamo, C., Sabbà, C., & Moschetta, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.9 · Cited by 424
Dietary Phosphorus Regulates Serum Fibroblast Growth Factor-23 Concentrations in Healthy Men
Antoniucci, D. M., Yamashita, T., & Portale, A. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0021 · Cited by 421
Shalhoub, V., Shatzen, E. M., Ward, S. C., Davis, J., Stevens, J., Bi, V., Renshaw, L., Hawkins, N., Wang, W., Chen, C., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61405 · Cited by 413
Kolek, O. I., Hines, E. R., Jones, M. D., LeSueur, L. K., Lipko, M. A., Kiela, P. R., Collins, J. F., Haussler, M. R., & Ghishan, F. K. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00243.2005 · Cited by 409
Update on fibroblast growth factor 23 in chronic kidney disease
Wolf, M. (2012) · Kidney International · doi:10.1038/ki.2012.176 · Cited by 391
Farrow, E. G., Yu, X., Summers, L. J., Davis, S. I., Fleet, J. C., Allen, M. R., Robling, A. G., Stayrook, K. R., Jideonwo, V., Magers, M. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110905108 · Cited by 380
Self-citationLorenz-Depiereux, B., Benet-Pages, A., Eckstein, G., Tenenbaum-Rakover, Y., Wagenstaller, J., Tiosano, D., Gershoni-Baruch, R., Albers, N., Lichtner, P., Schnabel, D., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/499410 · Cited by 379
Jean, G., Terrat, J.-C., Vanel, T., Hurot, J.-M., Lorriaux, C., Mayor, B., & Chazot, C. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp191 · Cited by 351
Insogna, K. L., Briot, K., Imel, E. A., Kamenický, P., Ruppe, M. D., Portale, A. A., Weber, T., Pitukcheewanont, P., Cheong, H. I., Jan de Beur, S., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3475 · Cited by 343
Self-citationHasegawa, H., Nagano, N., Urakawa, I., Yamazaki, Y., Iijima, K., Fujita, T., Yamashita, T., Fukumoto, S., & Shimada, T. (2010) · Kidney International · doi:10.1038/ki.2010.313 · Cited by 341
The new bone biology: Pathologic, molecular, and clinical correlates
Cohen Jr., M. M. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31368 · Cited by 335
Bai, X., Miao, D., Li, J., Goltzman, D., & Karaplis, A. C. (2004) · Endocrinology · doi:10.1210/en.2004-0233 · Cited by 329
Shigematsu, T., Kazama, J. J., Yamashita, T., Fukumoto, S., Hosoya, T., Gejyo, F., & Fukagawa, M. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.04.029 · Cited by 326
Ix, J. H., Katz, R., Kestenbaum, B. R., de Boer, I. H., Chonchol, M., Mukamal, K. J., Rifkin, D., Siscovick, D. S., Sarnak, M. J., & Shlipak, M. G. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.040 · Cited by 324
Fukumoto, S., & Martin, T. J. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.02.001 · Cited by 311
Forging Forward with 10 Burning Questions on FGF23 in Kidney Disease
Wolf, M. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121293 · Cited by 308
Perwad, F., Zhang, M. Y. H., Tenenhouse, H. S., & Portale, A. A. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00463.2006 · Cited by 300
Hormones and Disorders of Mineral Metabolism
Bringhurst, F. R., Demay, M. B., & Kronenberg, H. M. (2011) · Williams Textbook of Endocrinology · doi:10.1016/b978-1-4377-0324-5.00028-6 · Cited by 298
Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent
Berndt, T., Craig, T. A., Bowe, A. E., Vassiliadis, J., Reczek, D., Finnegan, R., Jan De Beur, S. M., Schiavi, S. C., & Kumar, R. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18563 · Cited by 293
Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia
Aono, Y., Yamazaki, Y., Yasutake, J., Kawata, T., Hasegawa, H., Urakawa, I., Fujita, T., Wada, M., Yamashita, T., Fukumoto, S., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090509 · Cited by 265
Wang, H., Yoshiko, Y., Yamamoto, R., Minamizaki, T., Kozai, K., Tanne, K., Aubin, J. E., & Maeda, N. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080220 · Cited by 263
FGF23 is processed by proprotein convertases but not by PHEX
Benet-Pagès, A., Lorenz-Depiereux, B., Zischka, H., White, K. E., Econs, M. J., & Strom, T. M. (2004) · Bone · doi:10.1016/j.bone.2004.04.002 · Cited by 258
Self-citationThe Structural Biology of the FGF19 Subfamily
Beenken, A., & Mohammadi, M. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-0887-1_1 · Cited by 93
Ubaidus, S., Li, M., Sultana, S., de Freitas, P. H. L., Oda, K., Maeda, T., Takagi, R., & Amizuka, N. (2009) · Journal of Electron Microscopy · doi:10.1093/jmicro/dfp032 · Cited by 85
Lo, Y.-C., Ji, D.-D., & Hung, C.-C. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003222 · Cited by 40
Physiopathology of Phosphate Disorders
Portales-Castillo, I., Rieg, T., Khalid, S. B., Nigwekar, S. U., & Neyra, J. A. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2022.12.011 · Cited by 26
Yuan, Y., Jagga, S., Martins, J. S., Rana, R., Pajevic, P. D., & Liu, E. S. (2021) · PLOS ONE · doi:10.1371/journal.pone.0252348 · Cited by 17
Yoon, C.-Y., Park, J., Seo, C., Nam, B. Y., Kim, S., Kee, Y. K., Lee, M., Cha, M.-U., Kim, H., Park, S., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2907 · Cited by 8
Metadata
- Authors
- Jonsson, K. B., Zahradnik, R., Larsson, T., White, K. E., Sugimoto, T., Imanishi, Y., Yamamoto, T., Hampson, G., Koshiyama, H., Ljunggren, Ö., Oba, K., Yang, I. M., Miyauchi, A., Econs, M. J., Lavigne, J., & Jüppner, H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-24
- Volume
- 348
- Issue
- 17
- Pages
- 1656-1663
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2094262605
- Cited by
- 914
- References
- 13
- FWCI
- 29.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.